Combined biolistic and cell penetrating peptide delivery for the development of scalable intradermal DNA vaccines DOI Creative Commons

Roizza Beth So,

Gang Li, Victoria A. Brentville

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 367, P. 209 - 222

Published: Jan. 26, 2024

Physical-based gene delivery via biolistic methods (such as the Helios gun) involve precipitation of nucleic acids onto microparticles and direct transfection through cell membranes exposed tissue (e.g. skin) by high velocity acceleration. The glycosaminoglycan (GAG)-binding enhanced transduction (GET) system exploits novel fusion peptides consisting cell-binding, acid condensing, cell-penetrating domains, which enable across multiple types. In this study, we combined chemical physical (gene DNA systems, hypothesized combination would generate distribution effective uptake in cells not initially transfected penetration. Physicochemical characterization, optimization bullet contents experiments vitro monolayers engineered demonstrated these formulations efficiently, including DC2.4 dendritic cells. We incorporated into a format for gun forming fireable dry bullets obtained lyophilization (freeze drying). This is simple with scalability compared to conventional bullets. Flushed GET retained their ability mediate (17-fold greater 13-fold reporter expression than standard spermidine absence presence serum, respectively). Fired (in collagen gels) vivo (mice) showed increased untreated controls, whilst maintaining viability having no obvious toxicity vivo. Lastly, SARS-CoV-2 plasmid vaccine spike (S) protein-receptor binding domain (S-RBD) was delivered using Specific T antibody responses comparable were generated. non-physical GET‑gold-DNA carriers shows potential an alternative method that scalable mass deployable vaccination intradermal delivery.

Language: Английский

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors DOI
Evan Tan,

Cara Sze Hui Chin,

Zhi Feng Sherman Lim

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2021, Volume and Issue: 9

Published: Dec. 13, 2021

Animal cell-based expression platforms enable the production of complex biomolecules such as recombinant proteins and viral vectors. Although most biotherapeutics are produced in animal cell lines, human lines is expanding. One important advantage using increased potential that resulting would carry more “human-like” post-translational modifications. Among HEK293 widely utilized due to its high transfectivity, rapid growth rate, ability grow a serum-free, suspension culture. In this review, we discuss use cells subtypes biotherapeutics. We also compare their usage against other commonly used host each category summarise factors influencing choice used.

Language: Английский

Citations

135
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities DOI Creative Commons
Majed Ghattas, Garima Dwivedi, Marc Lavertu

et al.

Vaccines, Journal Year: 2021, Volume and Issue: 9(12), P. 1490 - 1490

Published: Dec. 16, 2021

Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated, Virus-like Particles, synthetic peptide, polysaccharide, polysaccharide conjugate (glycoconjugate), viral vectored (vector-based), nucleic acids (DNA mRNA) bacterial vector/synthetic antigen presenting cells. Several processes are used the manufacturing vaccines recent developments medical/biomedical engineering, biology, immunology, vaccinology have led to emergence innovative acid vaccines, novel category added conventional subunit vaccines. In this review, we summarized advances vaccine technologies platforms focusing on their mechanisms action, advantages, possible drawbacks.

Language: Английский

Citations

125
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic DOI Creative Commons
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 682 - 682

Published: March 17, 2023

We are currently approaching three years since the beginning of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2 has caused extensive disruptions in everyday life, public health, and global economy. Thus far, vaccine worked better than expected against virus. During pandemic, we experienced several things, such as virus its pathogenesis, clinical manifestations, treatments; emerging variants; different vaccines; development processes. This review describes how each been developed approved with help modern technology. also discuss critical milestones during process. Several lessons were learned from countries two research, development, trials, vaccination. The process will to fight next

Language: Английский

Citations

66
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status DOI Creative Commons
Vivek P. Chavda, Rajashri Bezbaruah,

Disha Valu

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 432 - 432

Published: Feb. 13, 2023

The coronavirus disease (COVID-19) breakout had an unimaginable worldwide effect in the 21st century, claiming millions of lives and putting a huge burden on global economy. potential developments vaccine technologies following determination genetic sequence SARS-CoV-2 increasing efforts to bring vaccines therapeutics into market for emergency use have provided small bright spot this tragic event. Several intriguing candidates been developed using recombinant technology, engineering, other development technologies. In last decade, vast amount process has diversified towards usage viral vector-based vaccines. immune response elicited by such is comparatively higher than approved that require booster dose provide sufficient protection. non-replicating adenoviral vectors are promising carriers infectious diseases due better yield, cGMP-friendly manufacturing processes, safety, efficacy, manageable shipping, storage procedures. As April 2022, WHO total 10 around world COVID-19 (33 at least one country), among which three This review sheds light developmental summary all under authorization (EUA) or different stages management.

Language: Английский

Citations

56
T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses DOI Open Access
Elahe Aleebrahim‐Dehkordi,

Bahareh Molavi,

Melika Mokhtari

et al.

Transplant Immunology, Journal Year: 2021, Volume and Issue: 70, P. 101495 - 101495

Published: Nov. 10, 2021

Language: Английский

Citations

96
A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines DOI Open Access
Parisa Ghasemiyeh, Soliman Mohammadi‐Samani, Negar Firouzabadi

et al.

International Immunopharmacology, Journal Year: 2021, Volume and Issue: 100, P. 108162 - 108162

Published: Sept. 17, 2021

Language: Английский

Citations

88
Clinical development and approval of COVID-19 vaccines DOI
Ulrich Kalinke, Dan H. Barouch, Ruben Rizzi

et al.

Expert Review of Vaccines, Journal Year: 2022, Volume and Issue: 21(5), P. 609 - 619

Published: Feb. 14, 2022

The coronavirus 19 (COVID-19) pandemic triggered a simultaneous global demand for preventative vaccines, which quickly became high priority among governments as well academia and the pharmaceutical industry. Within less than year after COVID-19 was declared pandemic, vaccines had received emergency approvals vaccination campaigns were initiated.We discuss several factors that led to unprecedented, accelerated development approval of includes optimization processes by regulatory authorities, redesign sequential processes, learnings from previous pandemics, prior novel vaccine platforms.Despite unanticipated complex challenges presented real-time in context evolving subsequent ever-changing landscape public health measures recommendations, important milestones reached within extraordinarily short periods and, following roll-out billions worldwide, approved have proven be tolerated effective. Whilst this is an exceptional feat example what can achieved with collaboration innovation, there are lessons still learned, including need further harmonization between modes react pandemic's ever-evolving challenges, ensuring equitable access low-income countries.

Language: Английский

Citations

58
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena DOI Creative Commons
Vivek P. Chavda, Rajashri Bezbaruah,

Mansi Athalye

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(4), P. 759 - 759

Published: April 6, 2022

The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of human (CoV) that held accountable for current “coronavirus disease 2019 (COVID-19)” pandemic. In past two decades, world has witnessed emergence other similar CoVs, namely SARS-CoV in 2002 and MERS-CoV 2013. extent spread these earlier versions was relatively low comparison to SARS-CoV-2. Despite having numerous reports inclined towards zoonotic origin virus, one cannot simply sideline fact no animal originated CoV thus far identified considered initial edition SARS-CoV-2; however, under-sampling diverse variety coronaviruses remains a concern. Vaccines are proved be an effective tool bringing end such devastating Many vaccine platforms explored same but this review paper, we will discuss potential replicating viral vectors as carriers

Language: Английский

Citations

55
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens DOI Creative Commons
Lynda Coughlan, Eric J. Kremer, Dmitry M. Shayakhmetov

et al.

Molecular Therapy, Journal Year: 2022, Volume and Issue: 30(5), P. 1822 - 1849

Published: Jan. 31, 2022

Zoonotic viruses continually pose a pandemic threat. Infection of humans with for which we typically have little or no prior immunity can result in epidemics high morbidity and mortality. These public health economic impact exacerbate civil unrest political instability. Changes human behavior the past few decades-increased global travel, farming intensification, exotic animal trade, warming on migratory patterns, habitats, ecosystems-contribute to increased frequency cross-species transmission events. Investing pre-clinical advancement vaccine candidates against diverse emerging viral threats is crucial preparedness. Replication-defective adenoviral (Ad) vectors demonstrated their utility as an outbreak-responsive platform during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Ad are easy engineer; amenable rapid, inexpensive manufacturing; relatively safe immunogenic humans; and, importantly, do not require specialized cold-chain storage, making them ideal equitable distribution stockpiling. In this review, discuss progress applying Ad-based vaccines summarize safety profile, reflected by widespread geographic use SARS-CoV-2

Language: Английский

Citations

50
New Onset Biopsy-Proven Nephropathies after COVID Vaccination DOI Open Access
Roberta Fenoglio, Stefania Lalloni,

Martina Marchisio

et al.

American Journal of Nephrology, Journal Year: 2022, Volume and Issue: 53(4), P. 325 - 330

Published: Jan. 1, 2022

Introduction: To date, almost 7 billion doses of the different types vaccine against SARS-CoV-2 have been administered worldwide. Although severity new cases has progressively decreased, and pressure on national health systems declined, development de novo glomerular injuries suggested. Methods: This study aimed to examine patients who were hospitalized in our Unit between April November 2021 underwent renal biopsy for new-onset urinary abnormalities (UA) and/or impairment within 3 months vaccination. Results: We identified 17 developed UA insufficiency Minimal change disease was most common cohort (5 patients, 29.4%) followed by acute tubulointerstitial nephritis (TIN; 17.6%), membranous nephropathy (3 rapidly progressive IgA (2 11.8%). The other 4 had a diagnosis membranoproliferative glomerulonephritis (1 patient), systemic lupus erythematosus ANCA-associated vasculitis tip-variant focal segmental glomerulosclerosis respectively. Eight out (47.1%) kidney injury. Two with TIN start hemodialysis that discontinued after 1 2 months, respectively, due recovery function. All treatment corticosteroids immunosuppressants. Discussion: it is not possible conclusively determine whether there causal relationship vaccination nephropathies, based appearance shortly vaccination, we hypothesize immune response COVID-19 may be trigger nephropathies. Therefore, results highlight need pharmacovigilance. However, this report should lead hesitation during pandemic as benefits strongly outweigh potential risks.

Language: Английский

Citations

50